This content is in French.
CD47: The Tumor Shield Finally Broken?
3 février 2025
#cancer #immunotherapy #CD47 #innovation
Cancer remains one of the leading causes of mortality worldwide. And conventional treatments, such as surgery, chemotherapy, and radiotherapy, are often ineffective against advanced, metastatic, or resistant cancers. Immunotherapy, which uses the immune system to target cancer cells, represents a major breakthrough, particularly for cancers that are difficult to treat.
One of the most promising discoveries in this field is the understanding of the role of the CD47 protein, a molecule overexpressed on the surface of many cancer cells. It acts as a molecular shield by inhibiting phagocytosis, a key process in identifying and destroying abnormal cells. Tumors are able to evade the immune system, thus ensuring their growth and spread throughout the body.
Cancer remains one of the leading causes of mortality worldwide. And conventional treatments, such as surgery, chemotherapy, and radiotherapy, are often ineffective against advanced, metastatic, or resistant cancers. Immunotherapy, which uses the immune system to target cancer cells, represents a major breakthrough, particularly for cancers that are difficult to treat.
One of the most promising discoveries in this field is the understanding of the role of the CD47 protein, a molecule overexpressed on the surface of many cancer cells. It acts as a molecular shield by inhibiting phagocytosis, a key process in identifying and destroying abnormal cells. Tumors are able to evade the immune system, thus ensuring their growth and spread throughout the body.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Chen, Q., et al. (2024). Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Oncology Research, 32(1), 49
View the source
